Bacterial 30S ribosomal subunit secondary RNA site (30S secondary site)

The bacterial 30S ribosomal subunit secondary RNA site refers to auxiliary binding regions within the 16S ribosomal RNA (rRNA) that are distinct from the primary decoding A-site (Vicens & Westhof, 2001). While the primary site is the principal target for aminoglycoside antibiotics, these secondary sites provide additional points of interaction that enhance the drug's ability to disrupt bacterial protein synthesis (François et al., 2005). Binding at these locations contributes to the stabilization of the decoding center in an active state, which forces the ribosome to accept mismatched amino acids, resulting in the production of mistranslated, toxic proteins (Kohanski et al., 2010). These secondary interactions are particularly significant at higher therapeutic concentrations and are thought to play a role in the potent bactericidal activity of aminoglycosides compared to other protein synthesis inhibitors (Kotra et al., 2000). Clinically, these sites are the focus of treatment for severe infections caused by Gram-negative pathogens, including Pseudomonas aeruginosa and Enterobacteriaceae (StatPearls, 2023). However, the structural similarity between these bacterial RNA sites and human mitochondrial rRNA leads to significant safety concerns, such as permanent ototoxicity and nephrotoxicity (PubMed, 2022). Understanding the specific architecture of these secondary sites is vital for developing new antimicrobial agents that can bypass common resistance mechanisms like rRNA methylation (UniProt, 2023).

Other names

16S rRNA secondary binding siteAminoglycoside secondary siteNon-decoding 30S RNA siteHelix 44 secondary site30S ribosomal subunit auxiliary site

Aminoglycosides bind to secondary sites on the 16S rRNA of the 30S subunit, which, in conjunction with primary A-site binding, stabilizes the flipped-out conformation of adenine residues A1492 and A1493. This action reduces the energetic barrier for near-cognate tRNA binding, leading to significant mRNA misreading and the synthesis of aberrant proteins, while also inhibiting the translocation of the ribosome along the mRNA strand (Vicens & Westhof, 2001; Kohanski et al., 2010).